Israel - engelska - Ministry of Health

amgen europe b.v. - talimogene laherparepvec - solution for injection - talimogene laherparepvec 10^8 pfu / 1 ml - talimogene laherparepvec - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Israel - engelska - Ministry of Health

amgen europe b.v. - talimogene laherparepvec - solution for injection - talimogene laherparepvec 10^6 pfu / 1 ml - talimogene laherparepvec - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic ( stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Israel - engelska - Ministry of Health

amgen europe b.v. - etelcalcetide as hydrochloride - solution for injection - etelcalcetide as hydrochloride 5 mg / 1 ml - etelcalcetide - parsabiv is indicated for the treatment of secondary hyperparathyroidism (shpt) in adult patients with chronic kidney disease (ckd) on hemodialysis therapy.

Israel - engelska - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: - for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.- as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Israel - engelska - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: o for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.o in combination with isatuximab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.o as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Israel - engelska - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: o for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.o in combination with isatuximab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.o as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Israel - engelska - Ministry of Health

amgen europe b.v. - carfilzomib - powder for solution for injection - carfilzomib 2 mg/ml - carfilzomib - kyprolis is indicated: o for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy in combination with: • lenalidomide and dexamethasone; or • dexamethasone; or • daratumumab (i.v or s.c) and dexamethasone.o in combination with isatuximab and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.o as a single agent for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. approval is based on response rate. clinical benefit, such as improvement in survival or symptoms, has not been verified.

Saudiarabien - engelska - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen europe b.v., netherlands - darbepoetin alfa - solution for injection - 100 µ/ml

Saudiarabien - engelska - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen europe b.v., netherlands - darbepoetin alfa - solution for injection - 10 µ/ml

Saudiarabien - engelska - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

amgen europe b.v., netherlands - darbepoetin alfa - solution for injection - 150 µ/ml